국소 약물전달 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Topical Drug Delivery Market was valued at USD 156.3 billion in 2024 and is estimated to grow at a CAGR of 8.8% to reach USD 362.3 billion by 2034. This growth is largely driven by the increasing preference for non-invasive treatment methods and the widespread use of topical products for localized and systemic therapies. Topical drug delivery relies on administering active pharmaceutical ingredients through the skin or mucous membranes, offering a convenient and effective way to target specific areas without the need for oral ingestion or injections. With advancements in formulation technologies, these delivery systems now include a wide variety of applications such as gels, sprays, patches, ointments, and creams, each designed to maximize drug absorption and enhance therapeutic outcomes. As global healthcare trends shift towards self-care and chronic disease management at home, the demand for topical solutions continues to surge, particularly among patients seeking ease of use and minimal side effects.

The market is segmented by product type into liquid formulations, semi-solid formulations, solid formulations, and transdermal products. Semi-solid formulations held the largest market share, accounting for 62.1% of the total market revenue in 2024. This segment includes various subcategories such as creams, lotions, ointments, pastes, and gels, which are commonly used to treat a wide range of skin disorders and inflammatory conditions. Liquid formulations, which include suspensions and solutions, and solid formulations, comprising powders and suppositories, are also gaining traction. Meanwhile, transdermal products are split into patches and semi-solid types, offering controlled drug release and enhanced patient compliance.

The widespread occurrence of skin-related conditions such as acne, eczema, psoriasis, and dermatitis is fueling the need for effective treatment options, particularly those that are easy to apply and deliver targeted relief. As these chronic skin problems continue to rise globally, the demand for semi-solid topical solutions has grown significantly. Their practical benefits and ability to provide quick, localized relief make them a favored choice among both healthcare providers and patients.

In terms of delivery route, dermal drug delivery led the market with a revenue share of 58.7% in 2024. The prevalence of persistent skin conditions has pushed the adoption of dermal applications, which allow patients to treat affected areas directly. This approach is gaining popularity due to its user-friendly nature and effectiveness in managing long-term symptoms. Patients are increasingly leaning toward self-administered, non-surgical treatments that can be easily used in home settings without medical supervision, which supports further market expansion.

End-use segmentation shows that home care settings generated the highest revenue, reaching USD 66.9 billion in 2024. This segment's growth is supported by the rising need for convenient treatment solutions for chronic illnesses that require ongoing management. Topical therapies offer a safer, simpler alternative to oral or injectable medications, which often require professional assistance. As healthcare systems continue to emphasize outpatient care and home-based treatment options, the use of topical drug delivery systems is expected to expand.

Regionally, the U.S. market stood out, with values projected to grow from USD 59.1 billion in 2023 to an estimated USD 149 billion by 2034. This strong growth is fueled by high consumer awareness, increased healthcare spending, and a significant burden of dermatological conditions across the country. The accessibility of a wide range of topical products and growing investment in innovative drug delivery technologies also contribute to the region's dominance.

The global topical drug delivery landscape is highly competitive, with participation from both multinational corporations and smaller firms. Companies are channeling investments into developing advanced delivery systems such as microneedle technologies, smart wearables, and nanotechnology-driven platforms. These innovations aim to improve drug efficacy, extend release profiles, and enhance patient comfort. Additionally, partnerships between pharmaceutical manufacturers and healthcare research institutions are becoming a crucial part of the strategy to accelerate the adoption of cutting-edge therapies. Regulatory support, including simplified patent processes and faster drug approvals, is further encouraging innovation and intensifying competition in this rapidly evolving market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of skin and chronic diseases
    • 3.2.1.2 Advancements in formulation technologies
    • 3.2.1.3 Growing demand for self-administered treatments
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Skin irritation and limited permeability
    • 3.2.2.2 Regulatory challenges
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Retaliatory measures
  • 3.5.2 Impact on the Industry
    • 3.5.2.1 Supply-side impact (raw materials)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (selling price)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Technological landscape
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Semi-solid formulations
  • 5.2.1 Creams
  • 5.2.2 Ointments
  • 5.2.3 Lotions
  • 5.2.4 Gel
  • 5.2.5 Pastes
• 5.3 Liquid formulations
  • 5.3.1 Suspensions
  • 5.3.2 Solutions
• 5.4 Solid formulations
  • 5.4.1 Powders
  • 5.4.2 Suppositories
• 5.5 Transdermal products
  • 5.5.1 Transdermal patches
  • 5.5.2 Transdermal semi-solids

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Dermal drug delivery
• 6.3 Ophthalmic drug delivery
• 6.4 Rectal drug delivery
• 6.5 Vaginal drug delivery
• 6.6 Nasal drug delivery

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Home care settings
• 7.3 Hospitals and clinics
• 7.4 Burn centers
• 7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AbbVie
• 9.2 Bausch Health Companies
• 9.3 Bayer
• 9.4 Cipla
• 9.5 Eli Lilly and Company
• 9.6 Galderma Laboratories
• 9.7 GlaxoSmithKline
• 9.8 Johnson & Johnson
• 9.9 Merck
• 9.10 Novartis International
• 9.11 Pfizer
• 9.12 Sanofi
• 9.13 Sun Pharmaceutical Industries
• 9.14 Taro Pharmaceutical Industries
• 9.15 Teva Pharmaceutical Industries
• 9.16 Viatris